These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 10690558

  • 1. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
    Guo B, Cao S, Tóth K, Azrak RG, Rustum YM.
    Clin Cancer Res; 2000 Feb; 6(2):718-24. PubMed ID: 10690558
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S, McGuire JJ, Rustum YM.
    Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
    [Abstract] [Full Text] [Related]

  • 3. Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells.
    Guo B, Yin MB, Tóth K, Cao S, Azrak RG, Rustum YM.
    Oncol Res; 1999 Jul; 11(2):91-9. PubMed ID: 10489165
    [Abstract] [Full Text] [Related]

  • 4. The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer.
    Yin M, Hapke G, Guo B, Azrak RG, Frank C, Rustum YM.
    Oncogene; 2001 Aug 30; 20(38):5249-57. PubMed ID: 11536038
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
    Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM.
    Clin Cancer Res; 2004 Feb 01; 10(3):1121-9. PubMed ID: 14871992
    [Abstract] [Full Text] [Related]

  • 6. Synergistic antitumor activity of capecitabine in combination with irinotecan.
    Cao S, Durrani FA, Rustum YM.
    Clin Colorectal Cancer; 2005 Jan 01; 4(5):336-43. PubMed ID: 15663838
    [Abstract] [Full Text] [Related]

  • 7. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
    Bhattacharya A, Tóth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L, Azrak R, Cao S, Durrani FA, Rustum YM.
    Clin Cancer Res; 2004 Dec 01; 10(23):8005-17. PubMed ID: 15585636
    [Abstract] [Full Text] [Related]

  • 8. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
    Cao S, Durrani FA, Rustum YM.
    Clin Cancer Res; 2004 Apr 01; 10(7):2561-9. PubMed ID: 15073137
    [Abstract] [Full Text] [Related]

  • 9. Raltitrexed induces mitochondrial‑mediated apoptosis in SGC7901 human gastric cancer cells.
    Xue S, Chen YX, Qin SK, Yang AZ, Wang L, Xu HJ, Geng HY.
    Mol Med Rep; 2014 Oct 01; 10(4):1927-34. PubMed ID: 25109431
    [Abstract] [Full Text] [Related]

  • 10. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
    Bhattacharya A, Tóth K, Durrani FA, Cao S, Slocum HK, Chintala S, Rustum YM.
    Neoplasia; 2008 Aug 01; 10(8):857-65. PubMed ID: 18670644
    [Abstract] [Full Text] [Related]

  • 11. Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.
    Hapke G, Yin MB, Wu J, Frank C, Rustum YM.
    Int J Oncol; 2002 Nov 01; 21(5):1059-66. PubMed ID: 12370755
    [Abstract] [Full Text] [Related]

  • 12. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
    Yin MB, Li ZR, Tóth K, Cao S, Durrani FA, Hapke G, Bhattacharya A, Azrak RG, Frank C, Rustum YM.
    Oncogene; 2006 Apr 20; 25(17):2509-19. PubMed ID: 16518418
    [Abstract] [Full Text] [Related]

  • 13. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
    Azrak RG, Yu J, Pendyala L, Smith PF, Cao S, Li X, Shannon WD, Durrani FA, McLeod HL, Rustum YM.
    Mol Cancer Ther; 2005 May 20; 4(5):843-54. PubMed ID: 15897249
    [Abstract] [Full Text] [Related]

  • 14. Involvement of cyclin D1-cdk5 overexpression and MCM3 cleavage in bax-associated spontaneous apoptosis and differentiation in an A253 human head and neck carcinoma xenograft model.
    Yin MB, Tóth K, Cao S, Guo B, Frank C, Slocum HK, Rustum YM.
    Int J Cancer; 1999 Oct 29; 83(3):341-8. PubMed ID: 10495426
    [Abstract] [Full Text] [Related]

  • 15. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
    Pollack IF, Erff M, Bom D, Burke TG, Strode JT, Curran DP.
    Cancer Res; 1999 Oct 01; 59(19):4898-905. PubMed ID: 10519402
    [Abstract] [Full Text] [Related]

  • 16. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
    Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K.
    Cancer Chemother Pharmacol; 1991 Oct 01; 28(3):192-8. PubMed ID: 1855276
    [Abstract] [Full Text] [Related]

  • 17. Alteration of the Bcl-2/Bax status of head and neck cancer cell lines by chemotherapeutic agents.
    Kawakami K, Tsukuda M, Mizuno H, Nishimura G, Ishii A, Hamajima K.
    Anticancer Res; 1999 Oct 01; 19(5B):3927-32. PubMed ID: 10628333
    [Abstract] [Full Text] [Related]

  • 18. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R.
    Int J Oncol; 2002 Apr 01; 20(4):745-52. PubMed ID: 11894120
    [Abstract] [Full Text] [Related]

  • 19. [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
    Jerusalem G, Bours V, Fillet G.
    Rev Med Liege; 1998 Jun 01; 53(6):318-21. PubMed ID: 9713208
    [Abstract] [Full Text] [Related]

  • 20. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
    Ulrich-Pur H, Raderer M, Verena Kornek G, Schüll B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheithauer W.
    Br J Cancer; 2003 Apr 22; 88(8):1180-4. PubMed ID: 12698181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.